Jay H. Lubin

TL;DR: Based on limited data, there was a suggestion that spreading dose over time (from a few days to > 1 year) may lower risk, possibly due to the opportunity for cellular repair mechanisms to operate.

TL;DR: It was found that longer durations of recent, but not past, use of HRT increased breast cancer risk, particularly among leaner women and for tumors that were less clinically advanced.

TL;DR: In this article, the authors consider the regression of an environmental measurement (dependent variable) on several covariates (independent variables) and find that the fill-in approach generally produces unbiased parameter estimates but may produce biased variance estimates and thereby distort inference when 30% or more of the data are below detection limits.

TL;DR: Women who used estrogen-only replacement therapy, particularly for 10 or more years, were at significantly increased risk of ovarian cancer in this study.

TL;DR: The data suggest that the estrogen-progestin regimen increases breast cancer risk beyond that associated with estrogen alone, and were evident for the majority of invasive tumors with ductal histology and regardless of extent of invasive disease.